These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 12381851)

  • 21. Design and validation of a synthetic VH repertoire with tailored diversity for protein recognition.
    Almagro JC; Quintero-Hernández V; Ortiz-León M; Velandia A; Smith SL; Becerril B
    J Mol Recognit; 2006; 19(5):413-22. PubMed ID: 16881059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment.
    Arndt KM; Müller KM; Plückthun A
    Biochemistry; 1998 Sep; 37(37):12918-26. PubMed ID: 9737871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutual stabilization of VL and VH in single-chain antibody fragments, investigated with mutants engineered for stability.
    Wörn A; Plückthun A
    Biochemistry; 1998 Sep; 37(38):13120-7. PubMed ID: 9748318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Engineering antibodies for stability and efficient folding.
    Honegger A
    Handb Exp Pharmacol; 2008; (181):47-68. PubMed ID: 18071941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Promoting alpha-secretase cleavage of beta-amyloid with engineered proteolytic antibody fragments.
    Kasturirangan S; Brune D; Sierks M
    Biotechnol Prog; 2009; 25(4):1054-63. PubMed ID: 19572401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure and dynamics of the anti-AMCV scFv(F8): effects of selected mutations on the antigen combining site.
    Arcangeli C; Cantale C; Galeffi P; Rosato V
    J Struct Biol; 2008 Oct; 164(1):119-33. PubMed ID: 18662789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unraveling the effect of changes in conformation and compactness at the antibody V(L)-V(H) interface upon antigen binding.
    Pellequer JL; Chen Sw; Roberts VA; Tainer JA; Getzoff ED
    J Mol Recognit; 1999; 12(4):267-75. PubMed ID: 10440998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Probing the interaction between a high-affinity single-chain Fv and a pyrimidine (6-4) pyrimidone photodimer by site-directed mutagenesis.
    Kobayashi H; Morioka H; Tobisawa K; Torizawa T; Kato K; Shimada I; Nikaido O; Stewart JD; Ohtsuka E
    Biochemistry; 1999 Jan; 38(2):532-9. PubMed ID: 9888792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Catalytic antibody model and mutagenesis implicate arginine in transition-state stabilization.
    Roberts VA; Stewart J; Benkovic SJ; Getzoff ED
    J Mol Biol; 1994 Jan; 235(3):1098-116. PubMed ID: 8289310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selection and characterization of anti-MUC-1 scFvs intended for targeted therapy.
    Winthrop MD; DeNardo SJ; Albrecht H; Mirick GR; Kroger LA; Lamborn KR; Venclovas C; Colvin ME; Burke PA; DeNardo GL
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3845S-53S. PubMed ID: 14506182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The influence of the buried glutamine or glutamate residue in position 6 on the structure of immunoglobulin variable domains.
    Honegger A; Plückthun A
    J Mol Biol; 2001 Jun; 309(3):687-99. PubMed ID: 11397089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Probing the importance of second sphere residues in an esterolytic antibody by phage display.
    Arkin MR; Wells JA
    J Mol Biol; 1998 Dec; 284(4):1083-94. PubMed ID: 9837728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody.
    Lu D; Jimenez X; Witte L; Zhu Z
    Biochem Biophys Res Commun; 2004 May; 318(2):507-13. PubMed ID: 15120630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A semi-synthetic repertoire of intrinsically stable antibody fragments derived from a single-framework scaffold.
    Desiderio A; Franconi R; Lopez M; Villani ME; Viti F; Chiaraluce R; Consalvi V; Neri D; Benvenuto E
    J Mol Biol; 2001 Jul; 310(3):603-15. PubMed ID: 11439027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improving GPX activity of selenium-containing human single-chain Fv antibody by site-directed mutation based on the structural analysis.
    Xu J; Song J; Yan F; Chu H; Luo J; Zhao Y; Cheng X; Luo G; Zheng Q; Wei J
    J Mol Recognit; 2009; 22(4):293-300. PubMed ID: 19277948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The influence of the framework core residues on the biophysical properties of immunoglobulin heavy chain variable domains.
    Honegger A; Malebranche AD; Röthlisberger D; Plückthun A
    Protein Eng Des Sel; 2009 Mar; 22(3):121-34. PubMed ID: 19136675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains.
    Staelens S; Desmet J; Ngo TH; Vauterin S; Pareyn I; Barbeaux P; Van Rompaey I; Stassen JM; Deckmyn H; Vanhoorelbeke K
    Mol Immunol; 2006 Mar; 43(8):1243-57. PubMed ID: 16118019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stability engineering of antibody single-chain Fv fragments.
    Wörn A; Plückthun A
    J Mol Biol; 2001 Feb; 305(5):989-1010. PubMed ID: 11162109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kinetic analysis of engineered antibody-antigen interactions.
    Malmqvist M
    J Mol Recognit; 1994 Mar; 7(1):1-7. PubMed ID: 7527233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and characterization of three recombinant single chain antibody fragments (scFvs) directed against the CD19 antigen.
    Bejcek BE; Wang D; Berven E; Pennell CA; Peiper SC; Poppema S; Uckun FM; Kersey JH
    Cancer Res; 1995 Jun; 55(11):2346-51. PubMed ID: 7538901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.